Alendronate (Fosamax): Dosing, Effectiveness, Side Effects, and How It Compares to Other Osteoporosis Drugs

What Is Alendronate and How Does It Work?

Alendronate belongs to the nitrogen-containing bisphosphonate class and works by binding tightly to hydroxyapatite in bone mineral, then being taken up by osteoclasts, where it inhibits farnesyl pyrophosphate synthase, an enzyme in the mevalonate pathway. This disrupts osteoclast function and induces osteoclast apoptosis. The result is a net shift in favor of bone formation, raising bone mineral density (BMD) at the lumbar spine and hip over months to years of therapy. [1]

The FDA first approved alendronate in 1995 under the brand name Fosamax (Merck). Generic alendronate sodium became available in 2008 and now accounts for the large majority of prescriptions filled in the United States. A water-soluble effervescent tablet formulation, Binosto (70 mg once weekly), was approved later for patients who have difficulty swallowing standard tablets. [2]

Because alendronate has an extremely long skeletal half-life, estimated at more than 10 years, the drug continues to suppress bone resorption for some time even after a patient stops taking it. This pharmacokinetic property is the scientific basis for the concept of a "drug holiday." The American Society for Bone and Mineral Research (ASBMR) Task Force recommended in 2016 that for low-to-moderate fracture risk patients who have taken oral bisphosphonates for 5 years, a 1-to-2-year break is reasonable, with reassessment every 2 to 3 years thereafter. [3]

Who Should Take Alendronate? Approved Indications

The FDA has approved alendronate for five distinct indications. Each carries its own dosing schedule.

1. Treatment of postmenopausal osteoporosis (70 mg once weekly or 10 mg daily)
2. Prevention of postmenopausal osteoporosis in women who are not yet osteoporotic but are at risk (35 mg once weekly or 5 mg daily)
3. Treatment of osteoporosis in men (70 mg once weekly)
4. Treatment of glucocorticoid-induced osteoporosis in men and women receiving the equivalent of at least 7.5 mg prednisone per day (5 mg daily; 10 mg daily for postmenopausal women not on estrogen)
5. Treatment of Paget disease of bone (40 mg daily for 6 months) [4]

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation, BHOF) recommends initiating pharmacologic treatment in postmenopausal women and men aged 50 and older who have a hip or vertebral fracture, a T-score of -2.5 or lower at the spine or hip, or a T-score between -1.0 and -2.5 combined with a 10-year FRAX probability of major osteoporotic fracture at or above 20% or hip fracture probability at or above 3%. [5]

Fracture Reduction Evidence: The FIT Trials

The Fracture Intervention Trial (FIT) remains the foundation of alendronate's fracture-reduction evidence base. Two large sub-studies were conducted.

In the FIT Vertebral Fracture Arm (N=2,027 women with existing vertebral fractures and femoral neck T-score at or below -1.6), alendronate 5 mg daily for 2 years then 10 mg daily for 1 year reduced the risk of new vertebral fractures by 47% compared to placebo (relative risk 0.53; P<0.001) and hip fractures by 51% (relative risk 0.49; P<0.05). [6]

In the FIT Clinical Fracture Arm (N=4,432 women without baseline vertebral fracture), alendronate reduced clinical fractures by 36% in the subset with femoral neck T-scores at or below -2.5. [7]

Lumbar spine BMD increased by a mean of 8.8% from baseline over 3 years in FIT, and femoral neck BMD increased by 3.6%. These gains are clinically meaningful: each standard deviation increase in hip BMD is associated with roughly a 2.6-fold reduction in hip fracture risk. [8]

Dosing and Administration: Getting It Right Matters

Alendronate's oral bioavailability is only 0.6% to 0.7% under ideal conditions, and food, coffee, juice, or other medications taken within 30 to 60 minutes can reduce absorption by 60% or more. Correct administration is non-negotiable.

Standard dosing protocol:

• Take alendronate first thing in the morning, at least 30 minutes before the first food, beverage (other than plain water), or other medication.
• Swallow with a full 8-ounce glass (240 mL) of plain water only. Not mineral water. Not coffee.
• Remain upright (sitting, standing, or walking) for at least 30 minutes after taking the tablet to reduce esophageal contact time and risk of esophageal irritation. [4]

The 70 mg once-weekly tablet is therapeutically equivalent to 10 mg daily and is the preferred formulation because weekly dosing improves patient adherence. A 12-month study published in Osteoporosis International found adherence rates approximately 20% higher with weekly versus daily bisphosphonate regimens. [9]

Patients who miss a weekly dose should take it the morning after they remember, then return to their scheduled once-weekly day. They should not take two doses in the same day.

Side Effects and Safety Concerns

Alendronate's most common adverse effect is upper gastrointestinal irritation. Esophageal irritation, esophagitis, and, rarely, esophageal ulcers have been reported, almost always when patients did not follow the upright/fasting administration rules. Patients with Barrett esophagus, active esophageal disease, or inability to sit or stand upright for 30 minutes should not use oral bisphosphonates. [4]

Two rarer but frequently discussed adverse effects deserve specific attention.

Osteonecrosis of the jaw (ONJ). The risk of ONJ in osteoporosis patients taking oral alendronate at standard doses is estimated between 1 in 10,000 and 1 in 100,000 patient-treatment years. A 2015 systematic review in the Journal of Bone and Mineral Research found that the absolute risk in oral bisphosphonate users at osteoporosis doses is roughly 0.01% to 0.001%, far lower than in cancer patients receiving high-dose intravenous bisphosphonates. [10] Patients should complete major dental work before starting therapy if feasible, but fear of ONJ should not deter appropriate treatment in fracture-risk patients.

Atypical femoral fractures (AFF). Long-term bisphosphonate use (beyond 5 years) is associated with a small increased risk of subtrochanteric or diaphyseal femoral fractures. The absolute risk is estimated at 3.2 to 50 cases per 100,000 patient-years, increasing with longer duration of use. [3] Patients who report new thigh or groin pain during therapy warrant imaging. This risk is one reason clinicians reconsider duration of therapy at the 5-year mark.

Other side effects include musculoskeletal pain (bone, joint, or muscle), which the FDA added a black-box warning about in 2008, and very rare cases of uveitis and atrial fibrillation, the latter without a confirmed causal relationship in randomized controlled trial data. [4]

Renal dosing. Alendronate is contraindicated in patients with a creatinine clearance below 35 mL/min. No dose adjustment is required for mild-to-moderate renal impairment (CrCl 35-60 mL/min), though clinicians should monitor renal function. [4]

How Alendronate Compares to Other Osteoporosis Drugs

Choosing among the available agents depends on fracture history, renal function, adherence patterns, cost, and comorbidities. The table below and the discussion that follows give a practical side-by-side view.

Alendronate vs. Risedronate (Actonel)

Risedronate, available as 5 mg daily, 35 mg weekly, or 150 mg monthly, is the other widely used first-line oral bisphosphonate. The VERT-MN and VERT-NA trials (combined N=approximately 3,700) demonstrated 41% to 49% reductions in vertebral fracture risk with risedronate over 3 years. [11] Direct head-to-head fracture data between alendronate and risedronate are limited; both are considered equivalent first-line agents in the BHOF guidelines. Risedronate may be better tolerated gastrointestinally in some patients because its binding affinity to bone mineral is lower, meaning it is cleared from the esophagus more quickly. Risedronate is also available as a delayed-release formulation (Atelvia, 35 mg weekly) taken immediately after breakfast, which removes the fasting requirement and may improve tolerability for patients with significant GI sensitivity. [11]

Alendronate vs. Ibandronate (Boniva)

Ibandronate is available as 150 mg oral monthly or 3 mg intravenous every 3 months. The BONE trial (N=2,946) showed ibandronate 2.5 mg daily reduced vertebral fracture risk by 52% over 3 years. [12] No randomized controlled trial has demonstrated a statistically significant reduction in hip fracture risk with ibandronate. This is a meaningful clinical distinction: BHOF guidelines note that ibandronate's hip fracture efficacy is not established in randomized trial data, making it a second-line option rather than a preferred first-line agent for patients whose primary concern is hip fracture prevention. Cost-wise, generic ibandronate is similarly priced to generic alendronate. [5]

Alendronate vs. Zoledronic Acid (Reclast)

Zoledronic acid 5 mg, given as a single intravenous infusion once yearly, is the most potent bisphosphonate by binding affinity. The HORIZON-Key Fracture Trial (N=7,736 postmenopausal women) found zoledronic acid reduced vertebral fracture risk by 70%, hip fracture risk by 41%, and nonvertebral fracture risk by 25% over 3 years (all P<0.001). [13] Zoledronic acid is preferred when oral bisphosphonate adherence is poor or when GI intolerance precludes oral therapy. The main short-term side effect is an acute-phase reaction (flu-like symptoms, fever, myalgia) in approximately 32% of patients after the first infusion, typically resolving within 1 to 3 days and attenuated by pre-treatment with acetaminophen. Zoledronic acid is also the only bisphosphonate shown in a randomized trial (HORIZON-Recurrent Fracture Trial, N=2,127) to reduce mortality after hip fracture by 28%. [14]

Alendronate vs. Denosumab (Prolia)

Denosumab is not a bisphosphonate. It is a fully human monoclonal antibody that inhibits RANK ligand, blocking osteoclast formation and activity. Given as a 60 mg subcutaneous injection every 6 months by a clinician, denosumab has no renal contraindication and is often preferred for patients with chronic kidney disease or esophageal disease who cannot take bisphosphonates. The FREEDOM trial (N=7,808) showed denosumab reduced vertebral fracture risk by 68%, hip fracture risk by 40%, and nonvertebral fracture risk by 20% over 36 months (all P<0.001). [15]

A critical safety distinction: unlike bisphosphonates, denosumab does not persist in bone after discontinuation. Stopping denosumab without transitioning to another antiresorptive agent causes rapid bone loss and a significant rebound increase in vertebral fracture risk, sometimes called "rebound vertebral fractures." A 2019 analysis in the Journal of Bone and Mineral Research found that 7.1% of women who discontinued denosumab without subsequent therapy had multiple new vertebral fractures within 12 months. [16] Patients and prescribers must plan for a bisphosphonate transition at least 6 months before stopping denosumab if denosumab is to be discontinued.

Monitoring BMD During Alendronate Therapy

After starting alendronate, a follow-up dual-energy X-ray absorptiometry (DXA) scan at 1 to 2 years confirms a treatment response. The BHOF and the American Association of Clinical Endocrinologists (AACE) define a treatment response as a stable or increasing BMD plus no new fractures. A significant BMD decline (more than the least significant change for the specific DXA machine) or a new fracture on therapy should prompt reconsideration of adherence, calcium and vitamin D adequacy, and possible secondary causes of bone loss, such as malabsorption, hyperparathyroidism, or hyperthyroidism. [17]

Biochemical markers of bone turnover, particularly serum C-terminal telopeptide (CTX) and procollagen type 1 N-terminal propeptide (P1NP), can be used to assess early treatment response within 3 to 6 months, before DXA changes become apparent. The International Osteoporosis Foundation recommends a reduction in CTX of at least 25% to 30% from baseline as evidence of adequate antiresorptive response. [17]

Calcium and Vitamin D: The Necessary Foundation

No antiresorptive drug works optimally if a patient is vitamin D deficient. The BHOF recommends 1,000 to 1 to 200 mg of elemental calcium daily from diet plus supplements combined, and 800 to 1 to 000 IU of vitamin D3 daily for adults aged 50 and older. [5] Calcium carbonate should be taken with food for best absorption; calcium citrate can be taken without food and is preferred for patients on proton pump inhibitors or with achlorhydria.

Alendronate trials enrolled patients who were repleted with calcium and vitamin D; the fracture reductions cited from FIT reflect that standard. A patient taking alendronate but chronically vitamin D deficient may not achieve the same fracture benefit seen in the clinical trials.

Drug Interactions and Special Populations

Calcium supplements, antacids, and many other oral medications reduce alendronate absorption if taken within 30 minutes of the dose. NSAIDs combined with alendronate may additively increase upper GI risk, though the combination is not absolutely contraindicated. Aspirin and alendronate can be co-administered provided the administration window is respected.

Alendronate is listed as FDA Pregnancy Category C (pre-2015 labeling framework) and is generally avoided during pregnancy given the drug's skeletal retention and theoretical risk to fetal bone. Women of reproductive age who require bisphosphonate therapy should discuss this with their prescriber. [4]

For men with osteoporosis, alendronate 70 mg weekly is an FDA-approved option supported by a randomized trial showing 7.1% lumbar spine BMD gain and 2.5% femoral neck BMD gain over 2 years compared to placebo (P<0.001 for both). [18]

The Drug Holiday Decision

After 5 years of oral bisphosphonate therapy, the ASBMR Task Force guidelines recommend reassessing fracture risk to determine whether to continue, switch, or take a drug holiday. Patients who can safely take a holiday include those who have no history of hip or vertebral fracture, have a femoral neck T-score above -2.5, and have a low FRAX 10-year hip fracture probability (below 3%). A holiday of 2 to 3 years is reasonable in this group, with DXA and FRAX reassessment at the end. Patients with a prior hip or vertebral fracture, or who are at high ongoing risk, should continue active therapy, sometimes by switching to zoledronic acid or denosumab. [3]

The rationale for holidays is the residual antifracture effect from accumulated drug in bone mineral combined with the AFF risk reduction that comes from stopping chronic bisphosphonate exposure.